Corneal and conjunctival ocular surface

The corneal and conjunctival ocular surface is a complex anatomical and functional unit comprising the cornea, conjunctiva, and the overlying tear film (Gipson, 2007). It serves as the primary refractive element of the eye and acts as a critical physical and immunological barrier against environmental pathogens and irritants (StatPearls, 2023). This system is essential for maintaining optical clarity and protecting the internal structures of the eye from mechanical and microbial insults. While not a single molecular target, it is the primary site of action for topical ophthalmic medications used to treat ocular surface diseases (PubMed, 2021). Pathologies such as dry eye disease, keratitis, and conjunctivitis involve the breakdown of this surface's homeostasis, leading to inflammation and epithelial damage (DEWS II, 2017). Therapeutic interventions like cyclosporine and lifitegrast target specific molecular pathways within these tissues to reduce T-cell mediated inflammation (FDA, 2023). Other treatments, including artificial tears and secretagogues, focus on stabilizing the tear film and enhancing lubrication. Monitoring the health of this surface involves clinical markers like tear break-up time and corneal staining to assess epithelial integrity. Overall, the ocular surface is a vital therapeutic landscape for preserving vision and ensuring patient comfort in ophthalmology.

Other names

Ocular surfaceCornea and conjunctivaPreocular surface

Topical medications act on the ocular surface by inhibiting inflammatory cytokines, antagonizing lymphocyte function-associated antigen-1 (LFA-1), or providing physical lubrication to stabilize the tear film (FDA, 2023; PubMed, 2021).